Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELL | P14151 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95722 | 0.78 | CES2 (0.37) | TRPV4 | |
| SCHEMBL14435896 | 0.74 | SELL (0.32) | SELLSELPSELERAPGEF4NFE2L2 | |
| SCHEMBL9712347 | 0.74 | TSHR (0.35) | TRPV4 | |
| SCHEMBL2951474 | 0.74 | TRPV4 (0.31) | TRPV4 | |
| SCHEMBL80375 | 0.74 | TRPV4 (0.58) | TRPV4 | |
| SCHEMBL7300875 | 0.73 | TAAR1 (0.45) | HDAC1 | |
| SCHEMBL8116820 | 0.73 | HDAC1 (0.32) | HDAC1HDAC6 | |
| SCHEMBL8119705 | 0.73 | CA1 (0.32) | — | |
| SCHEMBL8119941 | 0.73 | — | — | |
| SCHEMBL96536 | 0.72 | RAPGEF4 (0.39) | RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080213891-A1 | RNAi Agents Comprising Universal Nucleobases | ALNYLAM PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | US | claimed |
| US-20210198669-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MUSCULAR DISORDERS AND DYSTROPHIES, STEROID SIDE EFFECTS, AND INFLAMMATION | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2021-07-01 | — | — | US | disclosed |
| CN-108367020-B | Method for inhibiting tumors by miR-200 family inhibition | 国立大学法人千叶大学 | 2021-06-18 | — | — | CN | disclosed |
| US-9035041-B2 | Process for triphosphate oligonucleotide synthesis | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8962580-B2 | Chemical modifications of monomers and oligonucleotides with cycloaddition | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150011608-A1 | iRNA Agents Targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
| US-20140045919-A1 | Folate Conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8507455-B2 | Folate conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130196434-A1 | ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8399248-B2 | Methods of using MIR34 as a biomarker for TP53 functional status | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110166198-A1 | RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166200-A1 | METHODS OF USING MIR210 AS A BIOMARKER FOR HYPOXIA AND AS A THERAPEUTIC AGENT FOR TREATING CANCER | ZHANG ZHAN | 2011-07-07 | — | — | US | disclosed |
| US-20110118337-A1 | Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer | MERCK SHARP & DOHME CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110105583-A1 | METHODS OF USING MIR34 AS A BIOMARKER FOR TP53 FUNCTIONAL STATUS | MERCK & CO., INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7919473-B2 | IRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100227909-A1 | COMPOSITIONS COMPRISING MIR34 THERAPEUTIC AGENTS FOR TREATING CANCER | MERCK SHARP & DOHME CORP. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100179309-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-07-15 | — | — | US | disclosed |
| US-20090247614-A1 | Folate Conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009091972-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090136957-A1 | Methods and compositions for regulating cell cycle progression via the miR-106B family | ROSETTA INPHARMATICS, LLC | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213891-A1 | RNAi Agents Comprising Universal Nucleobases | NOP2, NOP58, FBL | SELL 3564/4885SELP 3972/4885SELE 1953/4885 |
| US-20210198669-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MUSCULAR DISORDERS AND DYSTROPHIES, STEROID SIDE EFFECTS, AND INFLAMMATION | TNNC1, MYOF, MBNL1 | SELL 4418/4885SELP 3765/4885SELE 3660/4885 |
| US-20110166198-A1 | RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE | EIF2AK2, IRF3, NSUN2 | SELL 3850/4885SELP 3249/4885SELE 2863/4885 |
| US-20100179309-A1 | MODIFIED iRNA AGENTS | HNRNPA0, HNRNPA1, SNRPA | SELL 676/4885SELP 1181/4885SELE 571/4885 |
| US-20130196434-A1 | ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND | NSUN2, SNRPE, RNASE1 | SELL 2486/4885SELP 3397/4885SELE 910/4885 |
| US-20090247614-A1 | Folate Conjugates | FOLR2, FOLR1, NSUN2 | SELL 2040/4885SELP 1298/4885SELE 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.